Gaucher Disease – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Gaucher Disease – Pipeline Review, H1 2020’, provides an overview of the Gaucher Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gaucher Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gaucher Disease

– The report reviews pipeline therapeutics for Gaucher Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gaucher Disease therapeutics and enlists all their major and minor projects

– The report assesses Gaucher Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gaucher Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gaucher Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gaucher Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adienne Pharma & Biotech

Apollo Therapeutics LLC

AVROBIO Inc

Belrose Pharma Inc

Bioasis Technologies Inc

Biosidus SA

Blue Turtle Bio Technologies Inc

Erad Therapeutics Inc

Evox Therapeutics Ltd

Freeline Therapeutics Ltd

Generation Bio Co

Genzyme Corp

GT Gain Therapeutics SA

ILIAS Biologics Inc

ISU ABXIS Co Ltd

Johnson & Johnson

M6P Therapeutics

Orphazyme A/S

Prevail Therapeutics Inc

Sanofi

SmartPharm Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Vera Therapeutics Inc

Yuhan Corp

Table of Contents

Table of Contents

Introduction

Gaucher Disease - Overview

Gaucher Disease - Therapeutics Development

Gaucher Disease - Therapeutics Assessment

Gaucher Disease - Companies Involved in Therapeutics Development

Gaucher Disease - Drug Profiles

Gaucher Disease - Dormant Projects

Gaucher Disease - Discontinued Products

Gaucher Disease - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Gaucher Disease, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Gaucher Disease – Pipeline by Adienne Pharma & Biotech, H1 2020

Gaucher Disease – Pipeline by Apollo Therapeutics LLC, H1 2020

Gaucher Disease – Pipeline by AVROBIO Inc, H1 2020

Gaucher Disease – Pipeline by Belrose Pharma Inc, H1 2020

Gaucher Disease – Pipeline by Bioasis Technologies Inc, H1 2020

Gaucher Disease – Pipeline by Biosidus SA, H1 2020

Gaucher Disease – Pipeline by Blue Turtle Bio Technologies Inc, H1 2020

Gaucher Disease – Pipeline by Erad Therapeutics Inc, H1 2020

Gaucher Disease – Pipeline by Evox Therapeutics Ltd, H1 2020

Gaucher Disease – Pipeline by Freeline Therapeutics Ltd, H1 2020

Gaucher Disease – Pipeline by Generation Bio Co, H1 2020

Gaucher Disease – Pipeline by Genzyme Corp, H1 2020

Gaucher Disease – Pipeline by GT Gain Therapeutics SA, H1 2020

Gaucher Disease – Pipeline by ILIAS Biologics Inc, H1 2020

Gaucher Disease – Pipeline by ISU ABXIS Co Ltd, H1 2020

Gaucher Disease – Pipeline by Johnson & Johnson, H1 2020

Gaucher Disease – Pipeline by M6P Therapeutics, H1 2020

Gaucher Disease – Pipeline by Orphazyme A/S, H1 2020

Gaucher Disease – Pipeline by Prevail Therapeutics Inc, H1 2020

Gaucher Disease – Pipeline by Sanofi, H1 2020

Gaucher Disease – Pipeline by SmartPharm Therapeutics Inc, H1 2020

Gaucher Disease – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Gaucher Disease – Pipeline by Vera Therapeutics Inc, H1 2020

Gaucher Disease – Pipeline by Yuhan Corp, H1 2020

Gaucher Disease – Dormant Projects, H1 2020

Gaucher Disease – Dormant Projects, H1 2020 (Contd..1), H1 2020

Gaucher Disease – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Gaucher Disease, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports